PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34275396-11 2021 Early phase studies suggested the combinations of acalabrutinib with a CD20 antibody and venetoclax led to high rates of undetectable minimal residual disease in the bone marrow in CLL patients and might provide a fixed-duration therapeutic option for patients with CLL. acalabrutinib 50-63 keratin 20 Homo sapiens 71-75 30089638-11 2018 CD20 mAb-induced ADCP was not inhibited by venetoclax and was less inhibited by acalabrutinib versus ibrutinib and umbralisib versus idelalisib. acalabrutinib 80-93 keratin 20 Homo sapiens 0-4 34268530-6 2021 Acalabrutinib is approved as monotherapy in the R/R or TN setting, and in the TN setting can be combined with the anti-CD20 monoclonal antibody obinutuzumab. acalabrutinib 0-13 keratin 20 Homo sapiens 119-123 33093947-15 2020 Discussion: ACCEPT will provide evidence for whether acalabrutinib in combination with R-CHOP is safe and biologically effective prior to future Phase II/III trials in patients with previously untreated CD20 positive DLBCL. acalabrutinib 53-66 keratin 20 Homo sapiens 203-207 31915195-1 2020 Acalabrutinib is a selective irreversible Bruton tyrosine kinase inhibitor that does not affect interleukin-2 associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. acalabrutinib 0-13 keratin 20 Homo sapiens 250-254 28642301-0 2017 The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. acalabrutinib 46-59 keratin 20 Homo sapiens 154-158